French biotech Cor­te­ria se­cures $70M to re­vive ex-Sanofi heart drugs 

In­vestors are pump­ing $70 mil­lion in­to a Paris-based biotech’s at­tempt to re­vive two of Sanofi’s for­mer car­dio­vas­cu­lar pro­grams.

Cor­te­ria Phar­ma­ceu­ti­cals, found­ed in 2021, on Thurs­day un­veiled a €65 mil­lion ($70.7 mil­lion) Se­ries A round co-led by Or­biMed and Jeito Cap­i­tal that aims to ad­vance a se­ries of heart drugs in­to the clin­ic. Founders Philip Ja­ni­ak and Marie-Lau­re Ozoux hail from Sanofi, which an­nounced in 2019 that it was drop­ping car­dio and di­a­betes re­search.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER